Mineralys Therapeutics In... (MLYS)

Investors in the biotechnology space have been treated to a couple of big fireworks displays recently. During the month leading up to Sept.

There has been some speculation on Seeking Alpha recently on several biotech/biopharma names that make logical buyout targets. Many firms are on their way to success as standalone entities and have go...

Whether it's withering jobs data, renewed signs of inflation or sluggish consumer spending, there's been no shortage of concerning economic news over the past month. And yet, this gloomy backdrop has ...

Does Mineralys Therapeutics, Inc. (MLYS) have what it takes to be a top stock pick for momentum investors? Let's find out.

U.S. stock futures were mostly higher this morning, with the Nasdaq futures gaining around 150 points on Wednesday.

The average of price targets set by Wall Street analysts indicates a potential upside of 149.7% in Mineralys Therapeutics, Inc. (MLYS). While the effectiveness of this highly sought-after metric is qu...

Mineralys Therapeutics, Inc. (NASDAQ:MLYS ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Adam Scott Levy - CFO & Secretary Eric Warren - Chief Commercial Officer Jo...

Mineralys Therapeutics, Inc. (MLYS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The mean of analysts' price targets for Mineralys Therapeutics, Inc. (MLYS) points to a 154.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong ag...